The US FDA has recently given an in-principle nod for combination drug of glecaprevir and pibrentasvir for treating pediatric patients in between the age of 12 to 17 years for all genotypes of Hepatitis C virus. The combination was previously approved to treat HCV in adults. The antiviral drug is a direct-acting drug which holds its action against the virus and by preventing its replication and thereby decreasing the viral load in the body.
The FDC combination of Glecaprevir and pibrentasvir are marked as the first ever treatment for all genotypes of HCV, a viral disease deemed to cause cirrhosis of the liver which leads to devastating effects on liver rendering it defunct. Dosing information: It is recommended for adults or pediatric patients with 12 to 17 years of age and approximately 99 pounds in weight. Drug Information: Parameter Glecaprevir Pibrentasvir Description It is a…
